ARWR Arrowhead Pharmaceuticals, Inc.
USHealthcareAs of 2026-10-08
Why ARWR matters now
Arrowhead Pharmaceuticals, Inc. (ARWR) is a US stock in Healthcare. The latest InvestLog snapshot shows $60.74 with -1.20% on the session and $8.56B in market capitalization; recent performance reads 1-month +11.81% and YTD +23.24%.
The latest financial table shown here is Q2 2026, with revenue of $73.7M, net income of $-132.7M, and EPS of $-0.93. Investors can compare that operating picture with valuation signals such as P/E 45.10 and FCF yield -0.4%.
The latest indexable market news headline is "Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Breaks Below 200 Day Moving Average – Here’s Why" from Defense World.
Additional event context on this page matters because analyst consensus is Buy with a median target of $95.00; recent insider activity includes Cohen Matthew Gregory filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
45.10
PEG
0.34
P/B
18.98
P/S
18.53
EV/EBITDA
-94.52
DCF Value
$-99.57
FCF Yield
-0.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-35.7%
Net Margin
-48.4%
ROE
-55.4%
ROA
-13.3%
ROIC
-11.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $73.7M | $-132.7M | $-0.93 |
| Q1 2026 | $264.0M | $30.8M | $0.22 |
| Q4 2025 | $256.5M | $-23.8M | $-0.17 |
| FY 2025 | $829.4M | $-1.6M | $-0.01 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$84.00
Target (Median)
$95.00
Target Range
$35.00 - $110.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.27
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.